Cirrhosis: Difference between revisions
Ostermayer (talk | contribs) (Prepared the page for translation) |
Ostermayer (talk | contribs) (Marked this version for translation) |
||
| Line 2: | Line 2: | ||
<translate> | <translate> | ||
==Background== | ==Background== <!--T:1--> | ||
<!--T:2--> | |||
*A generally irreversible fibrotic scarring of the liver parenchyma resulting in liver failure | *A generally irreversible fibrotic scarring of the liver parenchyma resulting in liver failure | ||
*The twelfth leading cause of death in men and women in 2013<ref>Heron M. Deaths: Leading Causes for 2013. Natl Vital Stat Rep 2016: 16;65(2):1-95.</ref> | *The twelfth leading cause of death in men and women in 2013<ref>Heron M. Deaths: Leading Causes for 2013. Natl Vital Stat Rep 2016: 16;65(2):1-95.</ref> | ||
===Causes=== | ===Causes=== <!--T:3--> | ||
<!--T:4--> | |||
*[[Special:MyLanguage/Hepatitis|Hepatitis]] chronic B and C | *[[Special:MyLanguage/Hepatitis|Hepatitis]] chronic B and C | ||
*Alcoholic liver disease | *Alcoholic liver disease | ||
| Line 26: | Line 28: | ||
==Clinical Features== | ==Clinical Features== <!--T:5--> | ||
<!--T:6--> | |||
[[File:Jaundice08.jpg|thumb|Jaundice of the skin]] | [[File:Jaundice08.jpg|thumb|Jaundice of the skin]] | ||
[[File:SpiderAngioma.jpg|thumb|Spider angioma]] | [[File:SpiderAngioma.jpg|thumb|Spider angioma]] | ||
| Line 40: | Line 43: | ||
==Differential Diagnosis== | ==Differential Diagnosis== <!--T:7--> | ||
</translate> | </translate> | ||
| Line 50: | Line 53: | ||
==Evaluation== | ==Evaluation== <!--T:8--> | ||
<!--T:9--> | |||
[[File:Auscities.png|thumb|Ascites appearance on ultrasound]] | [[File:Auscities.png|thumb|Ascites appearance on ultrasound]] | ||
[[File:CirrhosisWithAscitesMark.png|thumb|Liver cirrhosis with ascites on CT]] | [[File:CirrhosisWithAscitesMark.png|thumb|Liver cirrhosis with ascites on CT]] | ||
===Workup=== | ===Workup=== <!--T:10--> | ||
<!--T:11--> | |||
*CBC | *CBC | ||
*Chem 7 | *Chem 7 | ||
| Line 65: | Line 70: | ||
===Diagnosis=== | ===Diagnosis=== <!--T:12--> | ||
==Management== | ==Management== <!--T:13--> | ||
<!--T:14--> | |||
'''Complications of cirrhosis''' | '''Complications of cirrhosis''' | ||
*[[Special:MyLanguage/Ascites|Ascites]] | *[[Special:MyLanguage/Ascites|Ascites]] | ||
| Line 80: | Line 86: | ||
*[[Special:MyLanguage/Hepatocellular carcinoma|Hepatocellular carcinoma]] | *[[Special:MyLanguage/Hepatocellular carcinoma|Hepatocellular carcinoma]] | ||
<!--T:15--> | |||
'''Pain management in cirrhotic patients''' | '''Pain management in cirrhotic patients''' | ||
*[[Special:MyLanguage/Acetaminophen|Acetaminophen]] is safe for short-term use at reduced dose of 2 grams total per day | *[[Special:MyLanguage/Acetaminophen|Acetaminophen]] is safe for short-term use at reduced dose of 2 grams total per day | ||
| Line 89: | Line 96: | ||
==Disposition== | ==Disposition== <!--T:16--> | ||
<!--T:17--> | |||
*Often complex and should be based on presence/absence of acute complications | *Often complex and should be based on presence/absence of acute complications | ||
*If no complications present, discussion with patient's primary care provider or gastroenterologist recommended | *If no complications present, discussion with patient's primary care provider or gastroenterologist recommended | ||
==Prognosis== | ==Prognosis== <!--T:18--> | ||
===Child-Pugh Score[http://www.mdcalc.com/child-pugh-score-for-cirrhosis-mortality/ <ref>Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64</ref>]=== | ===Child-Pugh Score[http://www.mdcalc.com/child-pugh-score-for-cirrhosis-mortality/ <ref>Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64</ref>]=== <!--T:19--> | ||
<!--T:20--> | |||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
| Line 115: | Line 124: | ||
|} | |} | ||
<!--T:21--> | |||
*Score ≤ 7 = Class A = 100% and 85% one and two-year patient survival | *Score ≤ 7 = Class A = 100% and 85% one and two-year patient survival | ||
*Score 7 - 9 = Class B = 80% and 60% one and two-year patient survival | *Score 7 - 9 = Class B = 80% and 60% one and two-year patient survival | ||
| Line 120: | Line 130: | ||
===MELD Score[http://www.mdcalc.com/meld-score-model-for-end-stage-liver-disease-12-and-older/ <ref>Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70.</ref>]=== | ===MELD Score[http://www.mdcalc.com/meld-score-model-for-end-stage-liver-disease-12-and-older/ <ref>Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70.</ref>]=== <!--T:22--> | ||
<!--T:23--> | |||
{| class="wikitable" | {| class="wikitable" | ||
|- | |- | ||
| Line 138: | Line 149: | ||
==See Also== | ==See Also== <!--T:24--> | ||
<!--T:25--> | |||
*[[Special:MyLanguage/Viral hepatitis|Viral hepatitis]] | *[[Special:MyLanguage/Viral hepatitis|Viral hepatitis]] | ||
*[[Special:MyLanguage/Acute hepatic failure|Acute hepatic failure]] | *[[Special:MyLanguage/Acute hepatic failure|Acute hepatic failure]] | ||
| Line 146: | Line 158: | ||
==External Links== | ==External Links== <!--T:26--> | ||
==References== | ==References== <!--T:27--> | ||
<!--T:28--> | |||
<references/> | <references/> | ||
<!--T:29--> | |||
[[Category:GI]] | [[Category:GI]] | ||
</translate> | </translate> | ||
Latest revision as of 12:31, 7 January 2026
Background
- A generally irreversible fibrotic scarring of the liver parenchyma resulting in liver failure
- The twelfth leading cause of death in men and women in 2013[1]
Causes
- Hepatitis chronic B and C
- Alcoholic liver disease
- Non-alcoholic steatohepatitis
- Drug induced (ie. Tylenol. amiodarone, NRTIs])
- Cardiac Cirrhosis
- Primary biliary cirrhosis
- Primary sclerosing cholangitis
- Autoimmune hepatitis
- Alpha1 anti-trypsin Deficiency
- Cystic Fibrosis
Sites of Portalcaval Anastomosis
Clinical presentations of portal hypertension include:
| Region | Name of clinical condition | Portal circulation | Systemic circulation |
| Esophageal | Esophageal varices | Esophageal branch of left gastric vein | Esophageal branches of azygos vein |
| Rectal | Rectal varices | Superior rectal vein | Middle rectal veins and inferior rectal veins |
| Paraumbilical | Caput medusae | Paraumbilical veins | Superficial epigastric vein |
| Retroperitoneal | Splenorenal shunt | Splenic vein | Renal vein, suprarenal vein, paravertebral vein, and gonadal vein |
| (no clinical name) | Right colic vein, middle colic vein, left colic vein | Retroperitoneal veins of Retzius | |
| Intrahepatic | Hepatic pseudolesions | Perihepatic veins of Sappey | Superior epigastric vein |
| Patent ductus venosus | Left branch of portal vein | Inferior vena cava |
A dilated inferior mesenteric vein may or may not be related to portal hypertension. Other areas of anastomosis include the bare area of the liver as it connects to the diaphragm, the posterior portion of the gastrointestinal tract as it touches the posterior abdominal wall, the posterior surface of the pancreas, and the inferior part of the esophagus.
Clinical Features
Ascites secondary to cirrhosis.
- May be asymptomatic initially
- Malaise, weakness (from electrolyte derangements)
- Abdominal pain
- Ascites, SBP (fever, abdominal tenderness)
- Altered mental status due to hepatic encephalopathy
- Coagulopathy
- GI bleed
Differential Diagnosis
Abdominal distention
- Obesity
- Intestinal obstruction
- Pregnancy
- Ascites
- Cirrhosis
- Malignancy
- Heart failure
- Tuberculosis
- Spontaneous bacterial peritonitis
- Peritoneal dialysis-associated peritonitis
- Distended bladder / Acute urinary retention
- Constipation / fecal impaction
- Large tumor(s) (e.g. ovarian, lymphoma)
- Organomegaly
Hepatic Dysfunction
Infectious
- Hepatitis
- Malaria
- HIV (present in 50% of AIDS patients)[2]
- EBV
- Babesiosis, leptospirosis
- Typhoid
- Hepatic abscess, amebiasis
Neoplastic
Metabolic
Biliary
- Biliary cirrhosis
Drugs
- Alcoholic cirrhosis
- Alcoholic hepatitis
- Hepatotoxic drugs
Miscellaneous
- Other causes of cirrhosis
- Autoimmune hepatitis
- Veno-occlusive disease
- CHF (right heart failure)
Evaluation
Workup
Diagnosis
Management
Complications of cirrhosis
- Ascites
- Esophageal varices
- Hepatic encephalopathy
- Spontaneous bacterial peritonitis
- Hepatorenal syndrome
- Portal hypertension
- Upper gastrointestinal bleed
- Hepatocellular carcinoma
Pain management in cirrhotic patients
- Acetaminophen is safe for short-term use at reduced dose of 2 grams total per day
- Gabapentin or pregabalin for neuropathic pain
- Avoid NSAIDs
- Avoid opioids
Disposition
- Often complex and should be based on presence/absence of acute complications
- If no complications present, discussion with patient's primary care provider or gastroenterologist recommended
Prognosis
Child-Pugh Score[3]
| +1 | +2 | +3 | |
|---|---|---|---|
| Bilirubin | <2mg/dL | 2-3mg/dL | >3 Mg/dL |
| Albumin | >3.5mg/dL | 2.8-3.5mg/dL | <2.8mg/dL |
| INR | <1.7 | 1.7-2.2 | >2.2 |
| Ascites | No ascites | Ascites, medically controlled | Ascites, poorly controlled |
| Encephalopathy | No encephalopathy | Encephalopathy, medically controlled | Encephalopathy, poorly controlled |
- Score ≤ 7 = Class A = 100% and 85% one and two-year patient survival
- Score 7 - 9 = Class B = 80% and 60% one and two-year patient survival
- Score ≥ 10 = Class c = 45% and 35% one and two-year patient survival
MELD Score[4]
| MELD-Na Score | 3-month mortality |
|---|---|
| 40 | 71.3% |
| 30-39 | 52.6% |
| 20-29 | 19.6% |
| 10-19 | 6.0% |
| <9 | 1.9% |
See Also
External Links
References
- ↑ Heron M. Deaths: Leading Causes for 2013. Natl Vital Stat Rep 2016: 16;65(2):1-95.
- ↑ Tintanelli's
- ↑ Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. Edited by CG Child. Philadelphia: Saunders 1964:50-64
- ↑ Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 Feb;33(2):464-70.